Search results for "Clinical science"

showing 10 items of 105 documents

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classificatio…

2016

AbstractThe IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyLung NeoplasmsStagingMedizinPrognostic factors1102 Cardiovascular Medicine And HaematologyLung cancer; Prognostic factors; Staging03 medical and health sciences0302 clinical medicineSeer programmedicineHumansOncology & CarcinogenesisStage (cooking)Lung cancerNeoplasm Stagingbusiness.industryGeneral surgeryInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions1103 Clinical SciencesPrognosismedicine.diseaseInternational Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplasm stagingBiostatisticsLung cancer stagingLung cancerbusinessSEER Program
researchProduct

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

2017

1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in…

0301 basic medicineRED YEAST RICEDiseasePharmacologyPLACEBO-CONTROLLED TRIALchemistry.chemical_compound0302 clinical medicineCARDIOVASCULAR RISK-FACTORSFamily historyhealth care economics and organizationseducation.field_of_studyCONJUGATED LINOLEIC-ACIDOrvostudományokGeneral MedicinehumanitiesC-REACTIVE PROTEIN3. Good healthDENSITY-LIPOPROTEIN CHOLESTEROL030220 oncology & carcinogenesislipids (amino acids peptides and proteins)nutraceuticalLife Sciences & Biomedicineposition paperMODERATELY HYPERCHOLESTEROLEMIC SUBJECTSmedicine.medical_specialtyRANDOMIZED CONTROLLED-TRIALSeducationPopulationGuidelines/RecommendationsKlinikai orvostudományok03 medical and health sciencesMedicine General & InternallipidGeneral & Internal MedicineInternal medicineDiabetes mellitusmedicineCORONARY-HEART-DISEASERisk factoreducationFATTY LIVER-DISEASEScience & TechnologyCholesterolbusiness.industrydyslipidemia1103 Clinical Sciencesmedicine.disease030104 developmental biologychemistryrecommendationsEtiologybusinessDyslipidemiaArchives of medical science : AMS
researchProduct

Tissue factor prothrombotic activity is regulated by integrin-arf6 trafficking

2017

Objective— Coagulation initiation by tissue factor (TF) is regulated by cellular inhibitors, cell surface availability of procoagulant phosphatidylserine, and thiol-disulfide exchange. How these mechanisms contribute to keeping TF in a noncoagulant state and to generating prothrombotic TF remain incompletely understood. Approach and Results— Here, we study the activation of TF in primary macrophages by a combination of pharmacological, genetic, and biochemical approaches. We demonstrate that primed macrophages effectively control TF cell surface activity by receptor internalization. After cell injury, ATP signals through the purinergic receptor P2rx7 induce release of TF + microvesicles. T…

0301 basic medicinedynaminsIntegrin alpha4CellCardiorespiratory Medicine and Haematology030204 cardiovascular system & hematologyIntegrin alpha4beta1Inbred C57BLTransgenicMicechemistry.chemical_compound0302 clinical medicineAdenosine TriphosphateCell-Derived MicroparticlesReceptors2.1 Biological and endogenous factorsfibrinGene Knock-In TechniquesAetiologyPhospholipidsTumorbiologyChemistryADP-Ribosylation FactorsHematologyPhosphatidylserineCell biologyProtein Transportmedicine.anatomical_structurePhenotypeProteomeextracellular vesiclesCardiology and Cardiovascular MedicinePurinergic P2X7BiotechnologySignal TransductionGenotypeproteomeClinical SciencesIntegrinMice TransgenicFactor VIIaTransfectionExtracellular vesiclesFibrinArticleCell LineThromboplastin03 medical and health sciencesTissue factorCell Line TumormedicineAnimalsHumansBlood CoagulationMacrophagesThrombosisMice Inbred C57BL030104 developmental biologyCardiovascular System & HematologyADP-Ribosylation Factor 6biology.proteinReceptors Purinergic P2X7
researchProduct

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

2021

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in nonalcoholic fatty liver disease (NAFLD), where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collect…

0301 basic medicinemedicine.medical_specialtyFIBROSIS STAGEBiomedical ResearchConsensusClinical SciencesImmunologyDiseaseMedical Biochemistry and MetabolomicsDIAGNOSISVALIDATIONArticle03 medical and health sciences0302 clinical medicineClinical ResearchNon-alcoholic Fatty Liver DiseaseEpidemiologyHealth caremedicineElectronic Health RecordsHumansGeneralizability theoryALGORITHMFATTY LIVER-DISEASEStatement (computer science)Gastroenterology & HepatologyHepatologybusiness.industryMORTALITYComparabilityClinical CodingReference Standards3. Good healthGood Health and Well Being030104 developmental biology3121 General medicine internal medicine and other clinical medicineFamily medicineInclusion and exclusion criteria030211 gastroenterology & hepatologyPatient SafetybusinessPsychologyREAL-WORLDCoding (social sciences)Hepatology
researchProduct

Consensus statement on the problem of terminology in psychological interventions using the internet or digital components

2020

Since the emergence of psychological interventions delivered via the Internet they have differed in numerous ways. The wealth of formats, methods, and technological solutions has led to increased availability and cost-effectiveness of clinical care, however, it has simultaneously generated a multitude of terms. With this paper, we first aim to establish whether a terminology issue exists in the field of Internet-delivered psychological interventions. If so, we aim to determine its implications for research, education, and practice. Furthermore, we intend to discuss solutions to mitigate the problem; in particular, we propose the concept of a common glossary. We invited 23 experts in the fie…

050103 clinical psychologyGlossarylcsh:BF1-990Clinical SciencesDelphi methodPsychological interventiondigital healthHealth Informatics610 Medicine & healthconsensus statementHealth informaticsTerminology03 medical and health sciences0302 clinical medicineterminologyInternet-delivered interventions0501 psychology and cognitive sciences030212 general & internal medicine610 Medicine & healthApplied PsychologyCommunications TechnologiesInternetlcsh:T58.5-58.64business.industrylcsh:Information technology05 social sciencesPublic relationsTillämpad psykologiTerminologyDigital healthFull length ArticleVariety (cybernetics)Psychotherapypsychotherapylcsh:PsychologyMental HealthConsensus statementPublic Health and Health ServicesThe InternetbusinessPsychologyDigital health
researchProduct

Analysis of performance and age of the fastest 100-mile ultra-marathoners worldwide

2013

OBJECTIVES: The performance and age of peak ultra-endurance performance have been investigated in single races and single race series but not using worldwide participation data. The purpose of this study was to examine the changes in running performance and the age of peak running performance of the best 100-mile ultra-marathoners worldwide. METHOD: The race times and ages of the annual ten fastest women and men were analyzed among a total of 35,956 finishes (6,862 for women and 29,094 for men) competing between 1998 and 2011 in 100-mile ultra-marathons. RESULTS: The annual top ten performances improved by 13.7% from 1,132±61.8 min in 1998 to 977.6±77.1 min in 2011 for women and b…

11035 Institute of General PracticeAdultMaleGerontologyFuture studies610 Medicine & health2700 General MedicineAthletic PerformanceRunningSex FactorsAthleteSex factorsHumansMedicineUltra-EnduranceSex DifferenceUltra enduranceMilelcsh:R5-920business.industryAge FactorsGeneral MedicineClinical SciencePhysical EnduranceFemalelcsh:Medicine (General)businessClinics
researchProduct

Sex differences in 24-hour ultra-marathon performance - A retrospective data analysis from 1977 to 2012

2013

OBJECTIVES: This study examined the changes in running performance and the sex differences between women and men in 24-hour ultra-marathons held worldwide from 1977 to 2012. METHOD: Changes in running speed and ages of the fastest 24-hour ultra-marathoners were determined using single- and multi-level regression analyses. RESULTS: From 1977 to 2012, the sex differences in 24-hour ultra-marathon performance were 4.6±0.5% for all women and men, 13.3% for the annual fastest finishers, 12.9±0.8% for the top 10 and 12.2±0.4% for the top 100 finishers. Over time, the sex differences decreased for the annual fastest finishers to 17%, for the annual 10 fastest finishers to 11.3±2.2% and for the ann…

11035 Institute of General PracticeGerontologyAdultMaleTime Factors610 Medicine & health2700 General MedicineAthletic PerformanceUltra marathonRetrospective dataRunningYoung AdultSex FactorsAthleteMedicineHumansUltra enduranceRetrospective Studieslcsh:R5-920biologybusiness.industryAthletesAge FactorsGeneral MedicineMiddle AgedClinical Sciencebiology.organism_classificationUltra-enduranceCross-Sectional StudiesPhysical EnduranceRegression AnalysisFemalelcsh:Medicine (General)businesshuman activities
researchProduct

Runners in their forties dominate ultra-marathons from 50 to 3,100 miles

2014

International audience; OBJECTIVES: This study investigated performance trends and the age of peak running speed in ultra-marathons from 50 to 3,100 miles. METHODS: The running speed and age of the fastest competitors in 50-, 100-, 200-, 1,000- and 3,100-mile events held worldwide from 1971 to 2012 were analyzed using single- and multi-level regression analyses. RESULTS: The number of events and competitors increased exponentially in 50- and 100-mile events. For the annual fastest runners, women improved in 50-mile events, but not men. In 100-mile events, both women and men improved their performance. In 1,000-mile events, men became slower. For the annual top ten runners, women improved in…

AdultMale11035 Institute of General PracticeGerontologyANTHROPOMETRYAge of Peak PerformanceTime FactorsPARTICIPATION610 Medicine & health2700 General MedicineAthletic PerformanceMuscle massUltra marathonRunningYoung AdultSex FactorsSex factorsHumansMedicineULTRAMARATHON RUNNERSMUSCLE MASSYoung adultUltra-Marathonlcsh:R5-920business.industryAEROBIC POWERRACE TIMEAge FactorsENDURANCEMOTIVATIONGeneral MedicineClinical ScienceMiddle AgedAnthropometryRunning SpeedPhysical EnduranceRegression AnalysisFemale[ SCCO ] Cognitive scienceRUNNING PERFORMANCEbusinesslcsh:Medicine (General)ULTRARUNNERSClinics
researchProduct

Contrast sensitivity and glare disability by halogen light after monofocal and multifocal lens implantation

2000

BACKGROUND—Standard examination of contrast sensitivity under conditions of glare disability is performed with incandescent light. A new halogen glare test that simulates glare as seen with oncoming vehicle headlights was used to measure glare disability in patients implanted with multifocal and monofocal intraocular lenses (IOLs). METHODS—28 patients with an average age of 69 years (SD 12 years) were implanted with a monofocal IOL (SI-40NB, Allergan) and 28 patients with an average of 66 years (12 years) were implanted with a refractive multifocal IOL (Array-SA-40N, Allergan). All patients were followed for 5 months postoperatively. Contrast sensitivity at four spatial frequencies (3, 6, 1…

AdultMaleAgingAutomobile Drivingmedicine.medical_specialtygenetic structuresEye diseasemedicine.medical_treatmentmedia_common.quotation_subjecteducationPoison controlIntraocular lensAstigmatismGlareContrast SensitivityVision disorderCellular and Molecular NeuroscienceHalogensOphthalmologymedicineHumansContrast (vision)Postoperative PeriodDioptreAgedmedia_commonAged 80 and overLenses Intraocularbusiness.industryGlare (vision)Middle AgedOriginal articles - Clinical sciencemedicine.diseaseeye diseasesSensory SystemsSurgeryOphthalmologyFemalesense organsmedicine.symptombusinessFollow-Up StudiesBritish Journal of Ophthalmology
researchProduct